Four Types of Pain
| Type | Definition | Character | Treatment Response |
|---|
| Nociceptive | Activation of peripheral nociceptors | Sharp, well-localized | Good response to NSAIDs, opioids |
| Visceral | Nociceptors in thoracic/abdominal organs | Diffuse, hard to localize | Variable; address underlying cause |
| Neuropathic | Injury to peripheral or central nervous system | Burning, shock-like, lancinating | Anti-neuropathic drugs (gabapentinoids, TCAs) |
| Nociplastic | Central processing dysfunction | No peripheral cause (fibromyalgia) | Brain-modulatory approaches |
Consciousness and Pain
Critical Finding
Pain requires a conscious brain. During general anesthesia, the patient is unconscious so there is no pain experience—yet nociception continues unabated (signals still hitting the spinal cord) and the stress response still occurs (cortisol, epinephrine surge). This is why multiple agents are needed: volatile anesthetic for unconsciousness plus opioid for nociception suppression.
Clinical Applications
Gate Control Theory
First proposed by Melzack and Wall in 1965, the gate control theory proposes that a mechanism in the dorsal horns of the spinal cord acts like a gate that inhibits or facilitates transmission from the body to the brain.4 This gate is influenced by:
| Input | Effect on Gate | Clinical Application |
|---|
| Aβ fiber activation (touch) | Closes gate, reduces pain | TENS units, rubbing injury |
| Descending brain pathways | Modulates gate | Psychological interventions, cognitive strategies |
| Inflammation | Opens gate | Anti-inflammatory medications |
| Sleep deprivation | Opens gate | Sleep optimization critical |
| Catastrophizing | Opens gate | CBT, pain psychology |
Practical example: Rubbing a bumped area activates Aβ fibers, which send inhibitory signals to the spinal cord where nociceptive fibers synapse—reducing pain perception.
Individual Pain Variability
Key Finding
When 500 people receive an identical 49°C heat stimulus, responses range from “barely felt it” to “10/10 excruciating.” The same individual can perceive identical stimulus differently day-to-day.
Factors influencing individual pain perception:
- Genetics (modality-specific: may tolerate heat but not cold)
- Sleep quality
- Emotional state
- Prior experiences
- Beliefs and expectations
- Early life adversity
- Current stress levels
Medication Guide
NSAIDs and Acetaminophen
| Medication | Mechanism | Dosing | Key Considerations |
|---|
| Ibuprofen | COX-2 inhibition, anti-inflammatory | 800 mg 3x/day (max 2,400 mg/day) | Take with food; GI/kidney risks |
| Naproxen | COX-2 inhibition, anti-inflammatory | 500 mg 2x/day | Longer acting; similar risks |
| Acetaminophen | Partially understood; some central effect | Up to 4g/day (some suggest 2g max) | Liver toxicity; limit with alcohol |
Key Insight
Synergy: Combining ibuprofen + acetaminophen provides a 1+1=3 effect due to different mechanisms. This reduces the dose needed of each. Individual response varies significantly—try both naproxen and ibuprofen to determine which works better.
Anti-Neuropathic Medications
| Drug | Mechanism | Dosing | Side Effects |
|---|
| Gabapentin | α2δ-1 calcium channel blocker | Up to 4g/day; max absorption ~1g/dose | Sedation, dizziness; no lethal dose |
| Pregabalin | Same mechanism, linear absorption | Variable; can dose higher than gabapentin | Similar; possible weight gain, edema |
| Tricyclic antidepressants | Serotonin/NE reuptake + sodium channel blocking | Varies by specific TCA | Sedation, anticholinergic effects |
Dosing strategy for gabapentinoids: Lower during day, higher at night (e.g., 300/300/600 gabapentin)—leverages sedative effect when most helpful.
Tricyclic Antidepressants for Pain
| TCA | Best For | Avoid In |
|---|
| Amitriptyline | Night dosing; sedation desired | Older men (prostate); weight-conscious patients |
| Desipramine | Less sedation needed | — |
| Nortriptyline | Titratable blood levels | — |
Note: TCAs work for pain independent of antidepressant effects—explain this to patients to avoid stigma.
Muscle Relaxants
| Drug | Use Case | Duration | Notes |
|---|
| Baclofen | Acute musculoskeletal flares | Days to weeks; safe long-term if beneficial | 20 mg 2–3x/day; non-habit-forming |
| Flexeril | Variable | Short-term preferred | Tricyclic properties; sedating |
| Soma | Avoid | — | Barbiturate-like; habit-forming |
Opioids: A Nuanced Approach
Context: The prescription opioid crisis resulted from a perfect storm of over-marketing by pharmaceutical companies, inadequate physician training (average 7 hours in medical school), pressure for patient satisfaction scores, shift from hospital to home-based post-operative care, and limited non-opioid alternatives at the time.
Risk factors for persistent opioid use post-surgery:
- Preoperative depression/anxiety
- High levels of catastrophizing
- History of PTSD
- Early adverse childhood events
- Self-loathing (strongest predictor)
Appropriate use framework: Not first-line agent. End-of-life and cancer pain: use liberally as needed. Acute perioperative: coordinate with pain service. Chronic: only after exhausting other options with ongoing monitoring.
Alternative and Emerging Therapies
Acupuncture
| Aspect | Finding |
|---|
| Mechanism | May activate peripheral nerves at acupuncture points; increases peripheral adenosine |
| Best evidence | Back pain, musculoskeletal pain, migraines/headaches |
| Predictability | Cannot reliably predict who will respond |
| Safety | Generally safe; ensure sterile technique |
Cannabis
Current status: Verdict still out. Some evidence for neuropathic pain, but a population-level Australian study showed no benefit. Patients coming to specialty clinics on cannabis are worse off. Challenges include unknown dose, unknown ratios, and insufficient study due to Schedule I status.
Low-Dose Naltrexone (LDN)
| Aspect | Detail |
|---|
| Mechanism | Blocks toll-like receptor 4 on microglia; reduces neuroinflammation |
| Standard dose | 4.5 mg (1/10th the addiction-treatment dose) |
| Conditions studied | Fibromyalgia, complex regional pain syndrome, MS, ulcerative colitis |
| Side effects | 20–30% get vivid dreams; rare activation (take morning instead) |
| Cost | ~$30/month; must be compounded; insurance often doesn’t cover |
| Safety | Decades of data at 10x dose; no severe adverse events reported in systematic reviews3 |
Key Finding
A 2024 meta-analysis of 4 RCTs (222 patients) found significant pain reduction with LDN (MD: −0.86, 95% CI: −1.20, −0.51, P < 0.001).3 An earlier crossover trial showed 28.8% pain reduction versus 18.0% with placebo.5
Fibromyalgia
Fibromyalgia syndrome: Widespread bodily pain above and below diaphragm with early morning stiffness, fatigue and “fibrofog,” sleep disturbances (alpha wave intrusion into deep sleep), and often GI problems.
Key Finding
People with fibromyalgia lack normal conditioned pain modulation (CPM)—the ability to inhibit pain in one area by causing pain in another. This suggests central processing dysfunction.
Treatment Approach
| Intervention | Notes |
|---|
| Duloxetine | SNRI; FDA-approved for pain; fewer side effects than TCAs |
| Gabapentinoids | Brain-modulatory drugs |
| Low-dose naltrexone | Address possible neuroinflammation |
| Sleep optimization | Critical; address alpha wave intrusion |
| Physical rehabilitation | Gradual, paced return to function |
| Pain psychology | Address catastrophizing, fear-avoidance |
The Biopsychosocial Model
Factors That Amplify Pain
| Category | Examples |
|---|
| Biological | Inflammation, poor glucose control (diabetic neuropathy), sleep deprivation |
| Psychological | Depression, anxiety, catastrophizing, fear-avoidance, low self-efficacy |
| Social | Isolation, loss of function, role changes, stigma |
Catastrophizing
Definition (Albert Ellis, 1962): Three components—amplification of pain, rumination (repetitive thoughts about pain), and sense of helplessness/loss of control.
Neurobiologic consequences:6
- Impairs dorsolateral prefrontal cortex function → reduced ability to down-regulate pain
- Heightened activity in anterior cingulate cortex, associated with emotional processing and pain modulation
- Gray matter volume reductions in prefrontal cortex observed in chronic pain patients who catastrophize
- Structural and functional brain alterations more pronounced in chronic pain patients, suggesting maladaptive plastic changes6
Sleep and Pain
Critical Finding
Sleep deprivation changes the brain’s set point for pain perception. It impairs prefrontal cortex modulation, creates descending facilitation (amplification) of pain signals, and chronic sleep disruption perpetuates the pain cycle. Pain management must include aggressive sleep optimization.
Recovery Framework
Breaking the Pain Cycle
- Acute intervention: Nerve blocks, medications, or procedures to break immediate cycle
- Enable rehabilitation: Pain reduction sufficient to allow movement and strengthening
- Physical rehabilitation: Rebuild strength, correct movement patterns, address deconditioning
- Psychological recovery: Develop self-efficacy, reduce catastrophizing, address fear-avoidance
- Social reconnection: Combat isolation; restore functional roles
Key Principles
| Principle | Application |
|---|
| Setbacks are temporary | Recovery isn’t linear; confidence builds with each recovery from setback |
| Breaking the cycle isn’t the cure | It enables the cure through rehabilitation |
| Self-efficacy is critical | Learning about your condition reduces fear and catastrophizing |
| Function over pain elimination | Goal is quality of life and control, not necessarily zero pain |
Expectations for Chronic Pain Recovery
- Pattern resembles stock market: overall improvement with short-term volatility
- Volatility decreases over time but never reaches zero
- Complete cure possible but not typical; aim for functional restoration
- Informed patients who understand their condition do better
Pre-Surgical Pain Optimization
Risk Stratification
Screen for factors predicting persistent post-surgical pain and opioid use: depression/anxiety scores, catastrophizing measures, history of trauma/PTSD, and early adverse childhood events.
Strategies to Reduce Post-Operative Opioid Need
| Strategy | Evidence |
|---|
| Pre-incision local anesthetic (bupivacaine + lidocaine + epi) | Significant reduction in opioid requirements |
| Scheduled acetaminophen + NSAID protocol | Maintains blood levels; better than PRN |
| Regional anesthesia/nerve blocks | Targeted pain control with less systemic effect |
| Pain service consultation | Coordinated multimodal plan |
Key Studies & Data
| Finding | Result | Significance |
|---|
| Chronic pain prevalence (2021)1 | 20.9% of U.S. adults (51.6 million) | Major public health burden |
| High-impact chronic pain1 | 6.9% of adults (17.1 million) | Substantial daily activity restrictions |
| Economic burden (2012)2 | $560–635 billion annually | Exceeds heart disease, cancer, diabetes combined |
| LDN meta-analysis (2024)3 | Significant pain reduction (MD: −0.86) | Emerging therapy with good safety profile |
| Gate control theory4 | Spinal modulation of pain signals | Foundation for TENS and neuromodulation therapies |
| Catastrophizing brain effects6 | Gray matter reduction in prefrontal cortex | Neurobiological basis for psychological interventions |
Additional Considerations
Study Limitations
- Low-dose naltrexone trials have been relatively small (typical n<100) with limited follow-up duration
- Pain is inherently subjective, making objective measurement challenging across studies
- Many chronic pain studies have high dropout rates, potentially biasing results
- Gate control theory, while influential, has been criticized for oversimplification of complex spinal mechanisms
Conflicting Evidence
- The FINAL trial (2024) did not show LDN superiority over placebo for fibromyalgia pain, though it suggested benefits for cognitive symptoms
- Cannabis research shows mixed results, with some trials positive and population-level studies showing no benefit
- Optimal opioid prescribing practices remain debated, with pendulum swings between over- and under-treatment
- Effectiveness of various psychological interventions varies significantly between individuals
Individual Variation
- Pain perception to identical stimuli varies enormously between individuals (from minimal to excruciating)
- Genetic factors influence both pain sensitivity and response to specific medications
- Early life adversity significantly impacts adult pain processing and treatment response
- Modality-specific sensitivity exists (some tolerate heat but not cold, or vice versa)
Safety Notes
- Acetaminophen toxicity remains a leading cause of acute liver failure—strict adherence to dosing limits essential
- NSAIDs carry significant GI, cardiovascular, and renal risks with long-term use
- Gabapentinoids may cause respiratory depression when combined with opioids
- Abrupt discontinuation of chronic pain medications can cause withdrawal syndromes
Evidence Gaps
- Long-term outcomes of multimodal pain management approaches are poorly characterized
- Optimal integration of pharmacological and psychological interventions needs more study
- Biomarkers to predict individual treatment response remain elusive
- The role of gut microbiome in pain processing is an emerging research area
Recent Developments
- FDA-approved new formulations aimed at abuse-deterrent opioids
- Growing interest in psychedelic-assisted therapy for chronic pain conditions
- Advances in neuromodulation including closed-loop spinal cord stimulation
- Research into glial cell modulators beyond LDN as novel analgesic targets
References
- Yong RJ, et al. (2022). Prevalence of chronic pain among adults in the United States. Pain, 163(2), e328–e332. DOI: 10.1097/j.pain.0000000000002291; CDC MMWR (2023). Chronic pain among adults—United States, 2019–2021.
- Gaskin DJ, Richard P. (2012). The economic costs of pain in the United States. Journal of Pain, 13(8), 715–724. DOI: 10.1016/j.jpain.2012.03.009
- Patten DK, et al. (2024). Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean Journal of Pain. DOI: 10.3344/kjp.24202
- Melzack R, Wall PD. (1965). Pain mechanisms: A new theory. Science, 150(3699), 971–979. DOI: 10.1126/science.150.3699.971
- Younger J, et al. (2013). Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism, 65(2), 529–538. DOI: 10.1002/art.37734
- Galambos A, et al. (2019). A systematic review of structural and functional MRI studies on pain catastrophizing. Journal of Pain Research, 12, 1155–1178. DOI: 10.2147/JPR.S192246
- Quartana PJ, et al. (2009). Pain catastrophizing: a critical review. Expert Review of Neurotherapeutics, 9(5), 745–758. DOI: 10.1586/ern.09.34
- Institute of Medicine. (2011). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. National Academies Press.
Medical Disclaimer: This educational brief is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any treatment regimen. Individual results may vary. The information presented reflects current research as of January 2026 and may be updated as new evidence becomes available.